Developing a rational approach to tobacco use treatment in pulmonary practice: A review of the biological basis of nicotine addiction

Clinical Pulmonary Medicine

Volumn 19, Issue 2, 2012, Pages 53-61

  Leone, Frank T ^a,b   Evers Casey, Sarah ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

behavioral medicine; counseling; nicotine addiction; nicotine biology; smoking cessation; tobacco dependence

Indexed keywords

AMFEBUTAMONE; CLONIDINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; PAROXETINE; VARENICLINE; VENLAFAXINE;

ADDICTION; AMBIVALENCE; BEHAVIOR CONTROL; CHRONIC DISEASE; CIGARETTE SMOKING; COMPULSION; DOCTOR PATIENT RELATION; DOPAMINERGIC ACTIVITY; DRUG MEGADOSE; EMOTIONAL STABILITY; ENVIRONMENTAL FACTOR; EUPHORIA; HUMAN; LONG TERM EXPOSURE; MOTIVATION; PATIENT ATTITUDE; PROFESSIONAL PRACTICE; PULMONOLOGY; REVIEW; SELF CONCEPT; SMOKING; SMOKING CESSATION; SMOKING HABIT; SURVIVAL FACTOR; TOBACCO DEPENDENCE; VENTRAL TEGMENTUM;

EID: 84858132301     PISSN: 10680640     EISSN: 15365956     Source Type: Journal    
DOI: 10.1097/CPM.0b013e318247cada     Document Type: Review

References (70)

1. McIlvain HE, Backer EL, Crabtree BF, et al. Physician attitudes and the use of office-based activities for tobacco control. Fam Med. 2002;34:114-119. (Pubitemid 34151079)
2. Morse DS, Edwardsen EA, Gordon HS. Missed opportunities for interval empathy in lung cancer communication. Arch Intern Med. 2008;168:1853-1858.
3. Centers for Disease Control and Prevention. Cigarette smoking among adults - United States, 1995. Morb Mortal Wkly Rep. 1997;46:1217-1220.
4. Hill HA, Schoenbach VJ, Kleinbaum DG, et al. A longitudinal analysis of predictors of quitting smoking among participants in a self-help intervention trial. Addict Behav. 1994;19:159-173. (Pubitemid 24144780)
5. Shiffman S, Scharf DM, Shadel WG, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol. 2006;74:276-285. (Pubitemid 43807360)
6. Burton SL, Gitchell JG, Shiffman S. Use of FDA-approved pharmacologic treatments for tobacco dependence-United States, 1984-1998. Morb Mortal Wkly Rep. 2000;49:665-668.
7. Shiffman S, Sweeney CT. Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability? Health Policy. 2008;86:17-26. (Pubitemid 351296300)
8. Hyland A, Rezaishiraz H, Giovino G, et al. Over-the-counter availability of nicotine replacement therapy and smoking cessation. Nicotine Tob Res. 2005;7:547-555.
9. Benowitz NL, Zevin S, Jacob P. Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther. 1998;287:958-962. (Pubitemid 29131607)
10. Lemmens V, Oenema A, Knut IK, et al. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. Eur J Cancer Prev. 2008;17:535-544.
11. Johnston LMGM. Tobacco smoking and nicotine. Lancet. 1941; 1:867.
12. Finnegan JK, Larson PS, Haag HB. The role of nicotine in the cigarette habit. Science. 1945;102:94-96.
13. Henningfield JE, Miyasato K, Jasinski DR. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther. 1985;234:1-12. (Pubitemid 15034883)
14. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289-294. (Pubitemid 16052281)
15. Alcaro A, Huber R, Panksepp J. Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res Rev. 2007;56:283-321. (Pubitemid 350176598)
16. Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol. 1989;40:191-225.
17. Abercrombie ED, Keefe KA, DiFrischia DS, et al. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem. 1989;52: 1655-1658. (Pubitemid 19109526)
18. Puglisi-Allegra S, Imperato A, Angelucci L, et al. Acute stress induces time-dependent responses in dopamine mesolimbic system. Brain Res. 1991;554:217-222.
19. Pruessner JC, Champagne F, Meaney MJ, et al. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci. 2004;24:2825-2831. (Pubitemid 38380960)
20. Ikemoto S, Panksepp J. The relationship between self-stimulation and sniffing in rats: does a common brain system mediate these behaviors? Behav Brain Res. 1994;61:143-162. (Pubitemid 24130912)
21. Mansvelder HD, Keath JR, McGehee DS. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron. 2002;33:905-919. (Pubitemid 34246356)
22. Azam L, Winzer-Serhan UH, Chen Y, et al. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. J Comp Neurol. 2002;444: 260-274. (Pubitemid 34117090)
23. Henningfield J. Behavioral pharmacology of cigarette smoking. Adv Behav Pharmacol. 1984;4:131-210.
24. Grove RN, Schuster CR. Suppression of cocaine self-administration by extinction and punishment. Pharmacol Biochem Behav. 1974;2:199-208.
25. Smith S, Davis W. Punishment of amphetamine and morphine self-administration behavior. Psychol Record. 1974;24: 477-480.
26. Stolerman I. Animal models for nicotine dependence. In: Bock G, Goode J, eds. Understanding Nicotine and Tobacco Addiction. Novartis Foundation Symposium 275. Chichester, UK: John Wiley and Sons; 2006:17-35.
27. Le Foll B, Wertheim C, Goldberg SR. High reinforcing efficacy of nicotine in non-human primates. PLoS One. 2007;2:e230.
28. Roberts DC, Koob GF. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol Biochem Behav. 1982;17:901-904. (Pubitemid 13208458)
29. Gong W, Neill D, Justice JB. 6-Hydroxydopamine lesion of ventral pallidum blocks acquisition of place preference conditioning to cocaine. Brain Res. 1997;754:103-112. (Pubitemid 27170257)
30. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev. 1998;28:309-369. (Pubitemid 29012677)
31. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berlin). 2007;191: 391-431. (Pubitemid 46355895)
32. Sienkiewicz-Jarosz H, Scinska A, Kuran W, et al. Taste responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatr. 2005;76:40-46. (Pubitemid 40013489)
33. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry. 2005;162:1414-1422. (Pubitemid 41105555)
34. Hebb D. The Organization of Behavior: A Neuropsychological Theory. New York: Wiley, 1949.
35. Morris RG, Hebb DO. The Organization of Behavior, Wiley: New York. Brain Res Bull. 1949;50:437.
36. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci. 2006;29:565-598. (Pubitemid 44476856)
37. Cooper DC. The significance of action potential bursting in the brain reward circuit. Neurochem Int. 2002;41:333-340.
38. Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993;33:23-29. (Pubitemid 23219906)
39. Isaac PF, Rand MJ. Blood levels of nicotine and physiological effects after inhalation of tobacco smoke. Eur J Pharmacol. 1969;8:269-283.
40. Lunell E, Molander L, Ekberg K, et al. Site of nicotine absorption from a vapour inhaler - comparison with cigarette smoking. Eur J Clin Pharmacol. 2000;55:737-741. (Pubitemid 30077569)
41. Legacy Tobacco Documents Library: AMMONIA (gfx65d00). Available at: http://legacy.library.ucsf.edu/tid/gfx65d00. Accessed November 30, 2009.
42. Legacy Tobacco Documents Library: Root Technology; A Handbook For Leaf Blenders and Product Developers (dlh01c00). Available at: http://legacy.library. ucsf.edu/tid/dlh01c00. Accessed November 30, 2009.
43. Ferris Wayne G, Connolly GN, Henningfield JE. Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents. Tob Control. 2006;15: 189-198. (Pubitemid 43864874)
44. Pankow JF, Tavakoli AD, Luo W, et al. Percent free base nicotine in the tobacco smoke particulate matter of selected commercial and reference cigarettes. Chem Res Toxicol. 2003;16: 1014-1018. (Pubitemid 37047919)
45. Siegel M, Nelson DE, Peddicord JP, et al. The extent of cigarette brand and company switching: results from the adult use-oftobacco survey. Am J Prev Med. 1996;12:14-16. (Pubitemid 26077383)
46. West R, Hajek P, Foulds J, et al. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berlin). 2000;149: 198-202. (Pubitemid 30262332)
47. Pascual MM, Pastor V, Bernabeu RO. Nicotine-conditioned place preference induced CREB phosphorylation and Fos expression in the adult rat brain. Psychopharmacology (Berlin). 2009;207: 57-71.
48. Aguilar MA, Rodríguez-Arias M, Miñarro J. Neurobiological mechanisms of the reinstatement of drug-conditioned place preference. Brain Res Rev. 2009;59:253-277.
49. Office of the Surgeon General (OSG). Tobacco cessation-you can quit smoking now! Available at: http://www.surgeongeneral. gov/tobacco/. Accessed December 10, 2009.
50. Sachs D, Leone F, Farber H, et al. ACCP Tobacco Dependence Treatment Toolkit. American College of Chest Physicians Tobacco-Dependence Treatment Tool Kit, 3rd ed. Available at: http://tobaccodependence.chestnet.org. Accessed November 8, 2010.
51. Swindell JS, McGuire AL, Halpern SD. Beneficent persuasion: techniques and ethical guidelines to improve patients' decisions. Ann Fam Med. 2010;8:260-264.
52. Lycan W. Mind and Cognition: An Anthology. 3rd ed. Malden, MA; Oxford: Blackwell Pub; 2008.
53. Smith D, Loewenstein G, Jepson C, et al. Mispredicting and misremembering: patients with renal failure overestimate improvements in quality of life after a kidney transplant. Health Psychol. 2008;27:653-658.
54. Smith DM, Sherriff RL, Damschroder L, et al. Misremembering colostomies? Former patients give lower utility ratings than do current patients. Health Psychol. 2006;25:688-695. (Pubitemid 44747851)
55. Miller W, Rollnick S. Motivational Interviewing: Preparing People to Change. New York: Guilford Press; 2002.
56. Leone FT, Evers-Casey S. Behavioral interventions in tobacco dependence. Prim Care: Clin Office Pract. 2009;36:489-507.
57. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2001; CD000146.
58. Silagy C, Mant D, Fowler G, et al. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 1994;343:139-142.
59. Fiore M, Jaén C, Baker T, et al. Treating Tobacco Use and Dependence: 2008 Update Clinical Practice Guideline. Rockville, MD: Department of Health and Human Services. Public Health Service; 2008.
60. Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med. 2002;346:506-512. (Pubitemid 34441743)
61. Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med. 2002;162: 1267-1276. (Pubitemid 34595033)
62. Foulds J, Stapleton J, Feyerabend C, et al. Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover study. Psychopharmacology (Berlin). 1992;106: 421-427.
63. Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6:159-166.
64. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs. 2000;59:1007-1024. (Pubitemid 30232332)
65. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-691. (Pubitemid 29110752)
66. Jamerson BD, Nides M, Jorenby DE, et al. Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clin Ther. 2001;23:744-752. (Pubitemid 32472605)
67. Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs. 2002;62(suppl 2):25-35.
68. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296: 56-63.
69. Tonstad S, Davies S, Flammer M, et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline. Drug Safety. 2010;33:289-301.
70. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64-71.